 |
|
Limited usefulness of calcimimetics for secondary hyperparathyroidism in non-dialysis chronic kidney disease
Fizza Abbas, Daniel W. Coyne
Kidney Res Clin Pract. 2019;38(2):141-144. Published online 2019 Jun 30 DOI: https://doi.org/10.23876/j.krcp.19.041
|
|
Citations to this article as recorded by
 Pharmacological Nephroprotection in Non-Diabetic Chronic Kidney Disease—Clinical Practice Position Statement of the Polish Society of Nephrology
Tomasz Stompór, Marcin Adamczak, Ilona Kurnatowska, Beata Naumnik, Michał Nowicki, Leszek Tylicki, Agata Winiarska, Magdalena Krajewska
Journal of Clinical Medicine.2023; 12(16): 5184. CrossRef The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation
Nahid Tabibzadeh, Angelo Karaboyas, Bruce M Robinson, Philipp A Csomor, David M Spiegel, Pieter Evenepoel, Stefan H Jacobson, Pablo-Antonio Ureña-Torres, Masafumi Fukagawa, Issa Al Salmi, Xinling Liang, Ronald L Pisoni, Eric W Young
Nephrology Dialysis Transplantation.2021; 36(1): 160. CrossRef Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency
Andrea Galassi, Paola Ciceri, Giulia Porata, Rossella Iatrino, Giulia Boni Brivio, Eliana Fasulo, Lorenza Magagnoli, Andrea Stucchi, Michela Frittoli, Anila Cara, Mario Cozzolino
Expert Opinion on Drug Safety.2021; 20(11): 1333. CrossRef Long‐term results of a randomized study comparing parathyroidectomy with cinacalcet for treating tertiary hyperparathyroidism
Pablo Moreno, Ana Coloma, José V. Torregrosa, Nuria Montero, José Francos, Sergi Codina, Anna Manonelles, Oriol Bestard, Arantxa García‐Barrasa, Edoardo Melilli, Josep M. Cruzado
Clinical Transplantation.2020;[Epub] CrossRef
|